Many corporate-backed funds remain enthusiastic venture investors, but some might be hitting the brakes.
The first quarter of 2021 saw fewer deals than any in recent memory.
The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.
Reliance on established drugs lessened for most large drug makers last year, but staleness is creeping in at Merck and Bristol.
The company might finally become an oncology player.
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.